Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

Purpose To investigate the efficacy and safety of neoadjuvant induction dose-dense MVAC (dd-MVAC) for muscle invasive bladder cancer (MIBC). Results of the 2-week-per-cycle regimen were compared with classic MVAC (4 weeks per cycle) and gemcitabine/cisplatin (GC, 3 weeks per cycle). Methods We inclu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	World journal of urology 2016-02, Vol.34 (2), p.157-162
Hauptverfasser:	van de Putte, Elisabeth E. Fransen, Mertens, Laura S., Meijer, Richard P., van der Heijden, Michiel S., Bex, Axel, van der Poel, Henk G., Kerst, J. Martijn, Bergman, Andries M., Horenblas, Simon, van Rhijn, Bas W. G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bladder cancer Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Cisplatin - administration & dosage Cisplatin - therapeutic use Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Dose-Response Relationship, Drug Doxorubicin - therapeutic use Female Follow-Up Studies Humans Male Medicine Medicine & Public Health Methotrexate - therapeutic use Middle Aged Neoplasm Invasiveness Nephrology Oncology Original Article Retrospective Studies Time Factors Treatment Outcome Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urology Vinblastine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!